HIP
CRSP icon

HUB Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

HUB Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$485K Buy
8,900
+1,500
+20% +$79.1K 0.01% 727
2026
Q1 		$352K Buy
7,400
+800
+12% +$42.2K 0.01% 726
2025
Q4 		$346K Buy
6,600
+3,100
+89% +$186K 0.01% 616
2025
Q3 		$227K Buy
3,500
+400
+13% +$23K 0.01% 650
2025
Q2 		$151K Buy
3,100
+1,000
+48% +$38.7K 0.01% 651
2025
Q1 		$71.5K Buy
+2,100
New +$89K ﹤0.01% 602

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HUB Investment Partners's CRSP Position: Q2 2026 in Review

HUB Investment Partners reduced its CRISPR Therapeutics (CRSP) stake by 59% in Q2 2026, selling an estimated $91.3K and leaving 1,201 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

HUB Investment Partners first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. The position peaked at $295K in Q2 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • HUB Investment Partners held 1,201 shares of CRISPR Therapeutics worth $65.5K as of Q2 2026.
  • HUB Investment Partners sold 1,733 CRISPR Therapeutics shares in Q2 2026, an estimated $91.3K.
  • CRISPR Therapeutics made up ﹤0.01% of HUB Investment Partners's portfolio in Q2 2026, its #1317 holding.
  • HUB Investment Partners first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • HUB Investment Partners's CRISPR Therapeutics position peaked at $295K in Q2 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on HUB Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.